Journal
CANCER LETTERS
Volume 271, Issue 1, Pages 47-55Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2008.05.041
Keywords
Anticancer peptide; Buforin IIb; Ganglioside; Histone H2A
Categories
Funding
- Ministry of Science and Technology of Korea [MG05-0204-1-0, M1-0106-00-0200]
- Korea Science and Engineering Foundation [R01-2005-000-11010-0]
- Korea Research Foundation [KRF-2004-042-O00072]
- National Research Foundation of Korea [MG05-0204-1-0, R01-2005-000-11010-0] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Buforin IIb is a novel cell-penetrating anticancer peptide derived from histone H2A. Here we analyzed the anticancer activity and cancer cell-killing mechanism of buforin IIb. Buforin IIb displayed selective cytotoxicity against 62 cancer cell lines by specifically targeting cancer cells through interaction with cell surface gangliosides. It traversed cancer cell membranes without damaging them and accumulated primarily in the nuclei. Once inside the cells, buforin IIb induced mitochondria-dependent apoptosis. In vivo analysis revealed that buforin IIb displayed significant tumor suppression activity in mice with tumor xenograft. Overall, these results suggest that buforin IIb constitutes a novel therapeutic agent for the treatment of cancers. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
